 |
Care of Patients with Chronic Noninfectious Posterior Uveitis
Presented by: Bausch + Lomb
For retinal physicians, there is another opportunity to treat a difficult disease. This supplement is edited by a special guest editor, Robert C. Wang, MD, a fellowship-trained expert in the diagnosis and treatment of uveitis. |
| |
|
 |
Surgical Experiences with the Stellaris PC System
Sponsored by:Bausch + Lomb
Presenters: Jeffrey S. Heier, MD (moderator); Andrew N. Antoszyk, MD; Kevin J. Blinder, MD; Derek Y. Kunimoto, MD, JD; Asheesh Tewari, MD and Kenneth J. Wald, MD
This new platform gives surgeons true "procedural choice" by providing advanced technology for vitreoretinal surgery and cataract surgery in a single system. A roundtable of surgeons discuss their professional experience with this new system. |
| |
|
 |
Introducing the Stellaris PC Vision Enhancement System
Sponsored by:Bausch + Lomb
Presenters: Carl C. Awh, MD; David R. Chow, MD, FRCSC; Philip Ferrone, MD; Tarek Hassan, MD and Suber S. Huang, MD, MBA
The new combined vitrectomy and phacoemulsification system is the latest innovation from Bausch + Lomb. A panel of renowned surgeons present their experience with this new, innovative system. Digital supplement includes videos of the presentations. |
| |
|
 |
Streamlining Your Retina Practice
Sponsored by:Genentech
The introduction of anti-VEGF therapy signaled a new era in retina practice. Learn how busy practices across the country ensure efficient delivery of this breakthrough treatment. |
| |
|
 |
Clinical Perspectives and Considerations With Retisert® (fluocinolone acetonide intravitreal implant) 0.59 mg in the Management of Chronic Non-infectious Uveitis of the Posterior Segment: Expertise Beyond the 3-year Follow-up Clinical Trial Data
Sponsored by:Bausch & Lomb
Presenters: Quan Dong Nguyen, MD, MSc, Panel Chair David G. Callanan, MD Debra A. Goldstein, MD, FRCSC Dean Eliott, MD Peter A. Netland, MD, PhD David G. Godfrey, MD Sunil K. Srivastava, MD
An expert panel of 7 uveitis, retina, and glaucoma specialists gathered in Chicago in August of 2009 to discuss the appropriate indications and applications of Retisert® (fluocinolone acetonide intravitreal implant) 0.59 mg. These specialists have extensive experience with the diagnosis and management of chronic non-infectious uveitis, the surgical placement and/or reimplantation of Retisert, and the medical and surgical management of ocular adverse events after implantation. In addition, two of the panel members were also investigators as part of the Fluocinolone Acetonide Study Group (Drs Callanan and Goldstein). |